Brian King, PhD, MPH, on Rehospitalization, Death Rates Among Patients With EVALI

In this podcast, Brian King, PhD, MPH, discusses his team's latest research on the prevalence of and risk factors for rehospitalization and death after discharge of patients with e-cigarette and vaping-related lung injury (EVALI), as well as comments on the current EVALI epidemic in the United States.

Additional Resources:

  • Mikosz CA, Danielson M, Anderson KN, et al; Lung Injury Response Epidemiology/Surveillance Task Force. Characteristics of patients experiencing rehospitalization or death after hospital discharge in a nationwide outbreak of e-cigarette, or vaping, product use–associated lung injury—United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;68(5152);1183-1188. http://dx.doi.org/10.15585/mmwr.mm685152e1
  • Hua M, Sarah S, Hristidis V, Talbot P. Health effects associated with electronic cigarette use: automated mining of online forums. J Med Internet Res. 2020;22(1):e15684. https://doi.org/10.2196/15684
  • Hartnett KP, Kite-Powell A, Patel MT, et al. Syndromic surveillance for e-cigarette, or vaping, product use–associated lung injury [published online December 20, 2019]. N Engl J Med. https://doi.org/10.1056/nejmsr1915313
  • Blount BC, Karwowski MP, Shields PG, et al; Lung Injury Response Laboratory Working Group. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI [published online December 20, 2019]. N Engl J Med. https://doi.org/10.1056/nejmoa1916433.  

Brian King, PhD, MPH, is the deputy director for Research Translation at the Office on Smoking and Health at the National Center for Chronic Disease Prevention and Health Promotion at the Centers for Disease Control and Prevention. He is also the senior official on the CDC’s response to the e-cigarette or vaping product-related lung injury. 

Submit Feedback

Name